A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

Priscila H. Goncalves, Lance K. Heilbrun, Michael Barrett, Shivaani Kummar, Aaron R. Hansen, Lillian L. Siu, Richard L. Piekarz, Ammar W. Sukari, Joseph Chao, Mary Jo Pilat, Daryn W. Smith, Lindsay Casetta, Scott A. Boerner, Alice Chen, Elizabeth Lenkiewicz, Smriti Malasi, Patricia M. LoRusso

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: Vorinostat is a histone deacetylase inhibitor (HDACi). Based on a confirmed partial response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior phase 1 trial, we initiated this phase 2 trial. Methods: Vorinostat was administered orally 400 mg daily, 28 day cycles. The primary objective was to evaluate response rate (RR). Exploratory studies included whole exome sequencing (WES) of selected patients. Results: Thirty patients were enrolled. Median age of patients was 53 years (range 21-73). Median number of cycles was 5 (range 1-66). Lymphopenia (n = 5), hypertension (n = 3), oral pain (n = 2), thromboembolic events (n = 2) and fatigue (n = 2) were the only grade 3 adverse events (AEs) that occurred in more than 1 patient. Eleven patients were dose reduced secondary to drug-related AEs. Two patients had a partial response (PR), with response durations of 53 and 7.2 months. One patient had a minor response with a decrease in ascites (for 19 cycles). Stable disease was the best response in 27 patients. Targeted and WES of 8 patients in this trial identified mutations in chromatin remodeling genes highlighting the role of the epigenome in ACC. Conclusion: Vorinostat demonstrated efficacy in patients with ACC supporting the inclusion of HDACi in future studies to treat ACC.

Original languageEnglish (US)
Pages (from-to)32918-32929
Number of pages12
JournalOncotarget
Volume8
Issue number20
DOIs
StatePublished - 2017

Fingerprint

Adenoid Cystic Carcinoma
Exome
Histone Deacetylase Inhibitors
vorinostat
Lymphopenia
Chromatin Assembly and Disassembly
Drug-Related Side Effects and Adverse Reactions
Ascites
Fatigue

Keywords

  • Adenoid cystic
  • SAHA
  • Salivary gland tumor
  • Suberoylanilide hydroxamic acid
  • Vorinostat

ASJC Scopus subject areas

  • Oncology

Cite this

Goncalves, P. H., Heilbrun, L. K., Barrett, M., Kummar, S., Hansen, A. R., Siu, L. L., ... LoRusso, P. M. (2017). A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget, 8(20), 32918-32929. https://doi.org/10.18632/oncotarget.16464

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. / Goncalves, Priscila H.; Heilbrun, Lance K.; Barrett, Michael; Kummar, Shivaani; Hansen, Aaron R.; Siu, Lillian L.; Piekarz, Richard L.; Sukari, Ammar W.; Chao, Joseph; Pilat, Mary Jo; Smith, Daryn W.; Casetta, Lindsay; Boerner, Scott A.; Chen, Alice; Lenkiewicz, Elizabeth; Malasi, Smriti; LoRusso, Patricia M.

In: Oncotarget, Vol. 8, No. 20, 2017, p. 32918-32929.

Research output: Contribution to journalArticle

Goncalves, PH, Heilbrun, LK, Barrett, M, Kummar, S, Hansen, AR, Siu, LL, Piekarz, RL, Sukari, AW, Chao, J, Pilat, MJ, Smith, DW, Casetta, L, Boerner, SA, Chen, A, Lenkiewicz, E, Malasi, S & LoRusso, PM 2017, 'A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma', Oncotarget, vol. 8, no. 20, pp. 32918-32929. https://doi.org/10.18632/oncotarget.16464
Goncalves, Priscila H. ; Heilbrun, Lance K. ; Barrett, Michael ; Kummar, Shivaani ; Hansen, Aaron R. ; Siu, Lillian L. ; Piekarz, Richard L. ; Sukari, Ammar W. ; Chao, Joseph ; Pilat, Mary Jo ; Smith, Daryn W. ; Casetta, Lindsay ; Boerner, Scott A. ; Chen, Alice ; Lenkiewicz, Elizabeth ; Malasi, Smriti ; LoRusso, Patricia M. / A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. In: Oncotarget. 2017 ; Vol. 8, No. 20. pp. 32918-32929.
@article{9dd1e844b1f1467b8b9a052ef3723d3e,
title = "A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma",
abstract = "Purpose: Vorinostat is a histone deacetylase inhibitor (HDACi). Based on a confirmed partial response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior phase 1 trial, we initiated this phase 2 trial. Methods: Vorinostat was administered orally 400 mg daily, 28 day cycles. The primary objective was to evaluate response rate (RR). Exploratory studies included whole exome sequencing (WES) of selected patients. Results: Thirty patients were enrolled. Median age of patients was 53 years (range 21-73). Median number of cycles was 5 (range 1-66). Lymphopenia (n = 5), hypertension (n = 3), oral pain (n = 2), thromboembolic events (n = 2) and fatigue (n = 2) were the only grade 3 adverse events (AEs) that occurred in more than 1 patient. Eleven patients were dose reduced secondary to drug-related AEs. Two patients had a partial response (PR), with response durations of 53 and 7.2 months. One patient had a minor response with a decrease in ascites (for 19 cycles). Stable disease was the best response in 27 patients. Targeted and WES of 8 patients in this trial identified mutations in chromatin remodeling genes highlighting the role of the epigenome in ACC. Conclusion: Vorinostat demonstrated efficacy in patients with ACC supporting the inclusion of HDACi in future studies to treat ACC.",
keywords = "Adenoid cystic, SAHA, Salivary gland tumor, Suberoylanilide hydroxamic acid, Vorinostat",
author = "Goncalves, {Priscila H.} and Heilbrun, {Lance K.} and Michael Barrett and Shivaani Kummar and Hansen, {Aaron R.} and Siu, {Lillian L.} and Piekarz, {Richard L.} and Sukari, {Ammar W.} and Joseph Chao and Pilat, {Mary Jo} and Smith, {Daryn W.} and Lindsay Casetta and Boerner, {Scott A.} and Alice Chen and Elizabeth Lenkiewicz and Smriti Malasi and LoRusso, {Patricia M.}",
year = "2017",
doi = "10.18632/oncotarget.16464",
language = "English (US)",
volume = "8",
pages = "32918--32929",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "20",

}

TY - JOUR

T1 - A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

AU - Goncalves, Priscila H.

AU - Heilbrun, Lance K.

AU - Barrett, Michael

AU - Kummar, Shivaani

AU - Hansen, Aaron R.

AU - Siu, Lillian L.

AU - Piekarz, Richard L.

AU - Sukari, Ammar W.

AU - Chao, Joseph

AU - Pilat, Mary Jo

AU - Smith, Daryn W.

AU - Casetta, Lindsay

AU - Boerner, Scott A.

AU - Chen, Alice

AU - Lenkiewicz, Elizabeth

AU - Malasi, Smriti

AU - LoRusso, Patricia M.

PY - 2017

Y1 - 2017

N2 - Purpose: Vorinostat is a histone deacetylase inhibitor (HDACi). Based on a confirmed partial response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior phase 1 trial, we initiated this phase 2 trial. Methods: Vorinostat was administered orally 400 mg daily, 28 day cycles. The primary objective was to evaluate response rate (RR). Exploratory studies included whole exome sequencing (WES) of selected patients. Results: Thirty patients were enrolled. Median age of patients was 53 years (range 21-73). Median number of cycles was 5 (range 1-66). Lymphopenia (n = 5), hypertension (n = 3), oral pain (n = 2), thromboembolic events (n = 2) and fatigue (n = 2) were the only grade 3 adverse events (AEs) that occurred in more than 1 patient. Eleven patients were dose reduced secondary to drug-related AEs. Two patients had a partial response (PR), with response durations of 53 and 7.2 months. One patient had a minor response with a decrease in ascites (for 19 cycles). Stable disease was the best response in 27 patients. Targeted and WES of 8 patients in this trial identified mutations in chromatin remodeling genes highlighting the role of the epigenome in ACC. Conclusion: Vorinostat demonstrated efficacy in patients with ACC supporting the inclusion of HDACi in future studies to treat ACC.

AB - Purpose: Vorinostat is a histone deacetylase inhibitor (HDACi). Based on a confirmed partial response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior phase 1 trial, we initiated this phase 2 trial. Methods: Vorinostat was administered orally 400 mg daily, 28 day cycles. The primary objective was to evaluate response rate (RR). Exploratory studies included whole exome sequencing (WES) of selected patients. Results: Thirty patients were enrolled. Median age of patients was 53 years (range 21-73). Median number of cycles was 5 (range 1-66). Lymphopenia (n = 5), hypertension (n = 3), oral pain (n = 2), thromboembolic events (n = 2) and fatigue (n = 2) were the only grade 3 adverse events (AEs) that occurred in more than 1 patient. Eleven patients were dose reduced secondary to drug-related AEs. Two patients had a partial response (PR), with response durations of 53 and 7.2 months. One patient had a minor response with a decrease in ascites (for 19 cycles). Stable disease was the best response in 27 patients. Targeted and WES of 8 patients in this trial identified mutations in chromatin remodeling genes highlighting the role of the epigenome in ACC. Conclusion: Vorinostat demonstrated efficacy in patients with ACC supporting the inclusion of HDACi in future studies to treat ACC.

KW - Adenoid cystic

KW - SAHA

KW - Salivary gland tumor

KW - Suberoylanilide hydroxamic acid

KW - Vorinostat

UR - http://www.scopus.com/inward/record.url?scp=85019255664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019255664&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16464

DO - 10.18632/oncotarget.16464

M3 - Article

VL - 8

SP - 32918

EP - 32929

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -